FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to gene therapy methods using the transcription factor 4 FOXP (FOXP4) gene, and can be used in medicine to reduce mammalian body weight. A nucleic acid encoding FOXP4, containing its expression vector, a method for its delivery to mammalian fat deposits, and a method for reducing mammalian body weight are proposed.
EFFECT: invention provides a means for effective reduction of mammalian body weight.
8 cl, 3 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MINI-PROTEIN USH2A, NUCLEIC ACID CODING MINI-PROTEIN USH2A, AND EXPRESSION VECTOR FOR GENE THERAPY CONTAINING SAME | 2023 |
|
RU2822884C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| USING VECTOR FOR REDUCING IMMUNE RESPONSE IN VIRAL DELIVERY OF AIPL1 | 2023 |
|
RU2818342C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| VECTORS AND SEQUENCES FOR TREATING DISEASES | 2011 |
|
RU2588667C2 |
| CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IV A | 2019 |
|
RU2794960C2 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS WITH PROTECTIVE PROPERTIES AGAINST INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2768044C1 |
